Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06080789 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis
A Phase 2 study of Acute Pancreatitis, sponsored by Panafina.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 36
- Enrollment target
- 14
- Study locations
NCT06080789: Recruiting Phase 2 study of Acute Pancreatitis, sponsored by Panafina.
NCT06080789 is a Phase 2 study of Acute Pancreatitis that is actively recruiting participants, run by Panafina. The registered enrollment target is 36 participants, below the 2,315-participant average among 10 other Acute Pancreatitis trials with a reported enrollment target (98% lower). The trial reports 14 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06080789, a Phase 2 study of Acute Pancreatitis, is actively recruiting participants, sponsored by Panafina.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 36 participants
- Enrollment target
- 14
- Study locations
Study Summary
The goal of this clinical trial is to test the safety and effectiveness of a single dose of RABI-767 given by endoscopic ultrasound (EUS) guided peripancreatic injection in participants with predicted severe acute pancreatitis. The main question the study aims to answer is: • Is a single-dose of RABI-767 given by EUS-guided peripancreatic injection safe in patients with predicted severe acute pancreatitis. The study also aims to answer: • Is a single-dose of RABI-767 given by EUS-guided peripancreatic injection effective in treating patients with predicted severe acute pancreatitis. Study participants will be randomly assigned (like the flip of a coin) to receive a single dose of RABI-767 plus supportive care or supportive care only. The study sponsor will compare safety and efficacy data collected from participants who receive RABI-767 to participants who receive supportive care only to test if RABI-767 is safe and effective.
Primary Outcome
An adverse event (AE) is defined as any untoward medical occurrence in a clinical study participant, temporally associated with the study intervention, regardless of its causal relationship to the study intervention. For the purposes of this study, any AE occurring in any study participant (regardless of treatment group assignment) at any time after enrollment/randomization, even if no study intervention has been administered, will be recorded.
Conditions Studied
Interventions
- DRUG RABI-767
Study Locations (14)
Florida
- University of Florida Health - Gainesville
- Orlando Health - Orlando
Arkansas
- University of Arkansas for Medical Sciences - Little Rock
California
- Keck Hospital of USC and LA County Hospital - Los Angeles
Colorado
- University of Colorado Anschutz Medical Campus - Aurora
Illinois
- UI Health, University of Illinois Chicago Hospital Health Sciences System - Chicago
Indiana
- Indiana University Health University Hospital - Indianapolis
Maryland
- Johns Hopkins Hospital - Baltimore
Michigan
- Henry Ford Hospital - Detroit
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2024-06-28 |
| Est. Completion | 2026-06 |
| Phase | Phase 2 |
What NCT06080789 shows while recruiting
NCT06080789 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 36 participants, a relatively small participant target, below the 2,315-participant average among 10 other Acute Pancreatitis trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Acute Pancreatitis appearing as the primary indexed condition, and to 1 intervention - of which RABI-767 is the first listed.
NCT06080789 lists 14 locations in 13 states (Florida, Arkansas, California).
Frequently Asked Questions
What is clinical trial NCT06080789 about?
NCT06080789 is a clinical study titled "A Study to Evaluate the Safety and Efficacy of a Single Dose of RABI-767 in Participants With Acute Pancreatitis". The goal of this clinical trial is to test the safety and effectiveness of a single dose of RABI-767 given by endoscopic ultrasound (EUS) guided peripancreatic injection in participants with predicted severe acute pancreatitis. The main question the study aims to answer is: • Is a single-dose of R...
What is the current status of trial NCT06080789?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 36 participants. The study started on 2024-06-28. Estimated completion is 2026-06.
What conditions does trial NCT06080789 study?
This clinical trial studies the following conditions: Acute Pancreatitis.
What interventions are being tested in trial NCT06080789?
The interventions under investigation include: RABI-767 (DRUG).
Who is sponsoring clinical trial NCT06080789?
This trial is sponsored by Panafina, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06080789 being conducted?
This trial has 14 study locations across Arkansas, California, Colorado, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Acute Pancreatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06080789's enrollment target sits among peer trials
36 9th of 10 higher than 2 of 10 other Acute Pancreatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Acute Pancreatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Auxora in Patients With Acute Pancreatitis and Accompanying SIRS
COMPLETED · Phase 2
-
DEciphering CIrculating SIgnatures Of Infected Pancreatic Necrosis
RECRUITING
-
iMmune SignAtures and Clinical outComes in AP
RECRUITING
-
Registry of Patients Undergoing Endoscopic Management of Pancreatic Fluid Collections
RECRUITING
-
Necrosectomy With Cryotechnology for Accelerated Removal
RECRUITING · NA
-
Collecting Medical Information and Tissue Samples From Patients With Pancreatic Cancer or Other Pancreatic Disorders
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00929006 · 36 participants · Early Phase 1
Acute Progesterone Suppression of Wake vs. Sleep Luteinizing Hormone Pulse Frequency in Pubertal Girls With and Without Hyperandrogenism
- NCT01891318 · 36 participants · Phase 1
Neoadjuvant Radiosurgery for Resectable Brain Metastases: Phase I/II Study
- NCT02291848 · 36 participants · Phase 1
Tumor-Associated Antigen-Specific Cytotoxic T-Lymphocytes for Multiple Myeloma
- NCT02366819 · 36 participants · Phase 4
Genetic Analysis-Guided Irinotecan Hydrochloride Dosing of mFOLFIRINOX in Treating Patients With Locally Advanced Gastroesophageal or Stomach Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI